Palatin Technologies, Inc.(PTNT.US)

Palamina Corp. Grants 4 Million Stock Options to Management and Advisors

Palamina Corp. has granted 4,025,000 stock options to its management and advisors under its Stock Option Plan, exercisable at $0.16 per share. The options for officers, directors, and advisors will expire on January 21, 2031, while those for consultants will expire on January 21, 2029. This announcement is for informational purposes only and should not be considered financial or legal advice.

Palatin Technologies, Inc. | 10-K: FY2025 Revenue: USD 0

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 | PTN Stock News

Palatin Technologies, Inc. presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for treating diabetic retinopathy at the ARVO 2025 Annual Meeting. The findings indicate that these compounds can resolve inflammation, stabilize the blood-retinal barrier, and protect retinal cells, showing efficacy across various models and administration routes. The results support further development of these agents, which could transform treatment for diabetic retinopathy, a leading cause of vision loss. Palatin aims to develop innovative therapies targeting the melanocortin receptor system.

Palatin Technologies closes public offering, transitions to OTC Pink (PTNT) on May 8, 2025.

In a move that took place on May 8, 2025, a company headquartered in Cranbury, New Jersey, Palatin Technologies, Inc., officially shifted to trading on the OTC Pink market. Known through the ticker symbol PTNT, Palatin Technologies is dedicated to creating innovative pharmaceutical solutions by harnessing the power of molecules that regulate melanocortin activity.

Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News

Palatin Technologies, Inc. has announced the closing of a reduced public offering, raising approximately $1.1 million through the sale of 7,324,119 shares of common stock and associated Series F, G, and H warrants. The offering was conducted with institutional and accredited investors at a price of $0.15 per share. Proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the lead placement agent. The company is focused on developing first-in-class biopharmaceuticals targeting the melanocortin receptor system.